P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03113487 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Platinum-Resistant Fallopian Tube Carcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Modified Vaccinia Virus Ankara Vaccine Expressing p53
BIOLOGICAL: Pembrolizumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]